Xcout Intel
Attune Pharmaceuticals, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Attune Pharmaceuticals, Inc. among biotechnology companies — ranked by similarity to what Attune Pharmaceuticals, Inc. actually does, not by market-cap band.
Subscribe to see Attune Pharmaceuticals, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Attune Pharmaceuticals, Inc.
Attune Biotech Inc. is a biopharmaceutical company that develops novel medicines to treat underserved disorders, focusing on neuroimmune, inflammatory, infectious disease, and metabolic applications. The company utilizes a proprietary platform approach featuring its flagship candidate, Lodonal, which is engineered with pharmaceutical-grade consistency and precision dosing to restore immune balance.
Attune Pharmaceuticals, Inc. at a glance
Attune Pharmaceuticals, Inc. is a biotechnology company headquartered in United States. Its most recent funding round, Series B, raised $23M in January 2019. Xcout tracks 3 named people at Attune Pharmaceuticals, Inc., including Dr. John Rosa (President and Interim Chief Medical Officer).
Attune Pharmaceuticals, Inc. leadership
- Dr. John RosaPresident and Interim Chief Medical Officer
- Glen FarmerChief Financial Officer
- Noreen GriffinFounder & CEO
Attune Pharmaceuticals, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $23M | 7 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Attune Pharmaceuticals, Inc. competitors
Ranked by semantic similarity — how close each company is to Attune Pharmaceuticals, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Biotech
Adaptin Bio is a biotechnology company developing a proprietary drug delivery platform designed to enhance the transfer of therapeutics across biological barriers into the brain and other targeted tissues. Its lead technology, the Brain Bispecific T cell Engager (BRiTE) platform, manipulates the human immune system to target diseases in oncology, central nervous system disorders, autoimmune conditions, and cardiovascular markets.
Similar biotechnology company
Attralus, Inc. is a biopharmaceutical company headquartered in Naples, Florida, focused on creating transformative medicines and novel pan-amyloid removal therapeutics and diagnostics.
Biotech
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
Similar biotechnology company
Autobahn Therapeutics is a biotechnology company headquartered in San Diego, California, focused on developing restorative treatments in the medical sector.
Similar biotechnology company
Autobahn Therapeutics, Inc. is a privately held biopharmaceutical company with its corporate office and headquarters located in San Diego, California, focused on restoring hope for patients.
Biotech
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Similar biotechnology company
Liminal BioSciences is a biopharmaceutical company headquartered in Laval, Quebec, Canada, focused on developing innovative small molecule therapeutics for inflammatory, fibrotic, and metabolic diseases.
Similar biotechnology company
Abalone Bio is a preclinical-stage biotechnology company headquartered in Emeryville, California, that develops therapeutic antibody drugs targeting GPCRs, ion channels, and other membrane proteins.
Similar biotechnology company
Tune Therapeutics, Inc. is a biotechnology company founded in 2020 that develops advanced genomic and epigenetic therapies, including epigenetic silencers.
Similar biotechnology company
Adventa Bioscience Inc. is a biotech firm that develops health and wellness products based on human milk. Its flagship product, Trulacta, is a daily dietary supplement containing Human Milk Bionutrients designed to support gastrointestinal and whole-body health.
Biotech
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Attune Pharmaceuticals, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Attune Pharmaceuticals, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →